phenyl 1H-pyrrolo[2,3-b]pyridin-5-ylcarbamate | 1020325-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: phenyl 1H-pyrrolo[2,3-b]pyridin-5-ylcarbamate
• 英文别名: (1H-pyrrolo[2,3-b]pyridin-5-yl)-carbamic acid phenyl ester；phenyl N-(1H-pyrrolo[2,3-b]pyridin-5-yl)carbamate
• CAS: 1020325-69-2
• 化学式: C₁₄H₁₁N₃O₂
• 分子量: 253.26
• InChiKey: BZFOHDUIRKFTEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  phenyl 1H-pyrrolo[2,3-b]pyridin-5-ylcarbamate 、 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 生成 7-[[3-(4-chlorophenoxy)phenyl]methyl]-N-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2,7-diazaspiro[3.5]nonane-2-carboxamide
  参考文献：
  名称：

  Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase

  摘要：

  A series of mechanism based heteroaryl urea fatty acid amide hydrolase (FAAH) inhibitors with spirocyclic diamine cores is described. A potent member of this class, (37), was found to inhibit FAAH centrally, elevate the brain levels of three fatty acid ethanolamides [FAAs: anandamide (AEA), oleoyl ethanolamide (OEA) and palmitoyl ethanolamide (PEA)], and was moderately efficacious in a rat model of neuropathic pain. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.113
• 作为产物：
  描述：

  5-氨基-7-氮杂吲哚 、 氯甲酸苯酯 在 吡啶 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 以23%的产率得到phenyl 1H-pyrrolo[2,3-b]pyridin-5-ylcarbamate
  参考文献：
  名称：

  Biaryl Ether Urea Compounds

  摘要：

  本发明涉及式(I)的化合物或其药用可接受的盐；制备该化合物的方法；制备该化合物所用的中间体；含有该化合物的组合物；以及利用该化合物治疗与脂肪酸酰胺水解酶(FAAH)活性相关的疾病或症状。

  公开号：

  US20080261941A1

文献信息

• Biaryl Ether Urea Compounds
  申请人：FAY Lorraine Kathleen

  公开号：US20080261941A1

  公开（公告）日：2008-10-23

  The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.

  本发明涉及式(I)的化合物或其药用可接受的盐；制备该化合物的方法；制备该化合物所用的中间体；含有该化合物的组合物；以及利用该化合物治疗与脂肪酸酰胺水解酶(FAAH)活性相关的疾病或症状。
• [EN] HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS D'URÉE SUBSTITUÉS PAR HÉTÉROARYLE D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010068453A1

  公开（公告）日：2010-06-17

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的哌啶基和哌嗪基脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物，并用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松症和运动障碍（例如多发性硬化）。
• [EN] HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE DE TYPE DIAMINE URÉE SPIROCYCLIQUE SUBSTITUÉE PAR UN GROUPE HÉTÉROARYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010141817A1

  公开（公告）日：2010-12-09

  Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

  描述了某些杂环取代的螺环二胺脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制药组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和条件的方法，如焦虑、疼痛、炎症、睡眠紊乱、进食紊乱、能量代谢紊乱和运动紊乱（例如多发性硬化）。
• [EN] ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS HETEROCYCLIQUES A BASE D'UREE A SUBSTITUTION ARYLE DE L'HYDROLASE DES AMIDES D'ACIDES GRAS (FAAH)
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010141809A1

  公开（公告）日：2010-12-09

  Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

  描述了某些含芳基取代的杂环脲化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物，并用于治疗由脂肪酰胺水解酶(FAAH)活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、能量代谢障碍和运动障碍(例如多发性硬化)。
• Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase
  作者：John M. Keith、William Jones、Joan M. Pierce、Mark Seierstad、James A. Palmer、Michael Webb、Mark Karbarz、Brian P. Scott、Sandy J. Wilson、Lin Luo、Michelle Wennerholm、Leon Chang、Michele Rizzolio、Raymond Rynberg、Sandra Chaplan、J. Guy Breitenbucher

  DOI：10.1016/j.bmcl.2020.127463

  日期：2020.10

  A series of mechanism-based heteroaryl urea fatty acid amide hydrolase (FAAH) inhibitors with fused bicyclic diamine cores is described. In contrast to compounds built around a piperazine core, most of the fused bicyclic diamine bearing analogs prepared exhibited greater potency against rFAAH than the human enzyme. Several compounds equipotent against both species were identified and profiled in vivo

  描述了一系列基于机制的具有稠合双环二胺核的杂芳基脲脂肪酸酰胺水解酶（FAAH）抑制剂。与围绕哌嗪核心构建的化合物形成对比，大多数制备的带有稠合双环二胺的类似物对rFAAH的抑制作用均比人类酶高。在体内鉴定并鉴定了对两种物种均等的几种化合物。